代谢和减肥手术与胰高血糖素样肽-1受体激动剂治疗：肥胖患者心血管结局的比较

IF 2.7 3区医学 Q1 SURGERY American journal of surgery Pub Date : 2025-04-01 Epub Date: 2025-02-08 DOI:10.1016/j.amjsurg.2025.116242

Soban Maan , Amir H. Sohail , Samia Aziz Sulaiman , Linta Mansoor , Ethan M. Cohen , Ayowumi A. Adekolu , Salim Abunnaja , Nova Szoka , Lawrence E. Tabone , Shyam Thakkar , Shailendra Singh

{"title":"代谢和减肥手术与胰高血糖素样肽-1受体激动剂治疗：肥胖患者心血管结局的比较","authors":"Soban Maan , Amir H. Sohail , Samia Aziz Sulaiman , Linta Mansoor , Ethan M. Cohen , Ayowumi A. Adekolu , Salim Abunnaja , Nova Szoka , Lawrence E. Tabone , Shyam Thakkar , Shailendra Singh","doi":"10.1016/j.amjsurg.2025.116242","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>This study compared cardiovascular outcomes associated with metabolic and bariatric surgery (MBS) and glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy in individuals with obesity.</div></div><div><h3>Methods</h3><div>The TriNetX network was used to compare cardiovascular risk in adult patients with BMI ≥35 who underwent MBS with those who received GLP-1 RA therapy for ≥2 years. Primary outcome was cardiovascular disease (CVD), a composite of incident heart failure (HF), coronary artery disease (CAD), and cerebrovascular disease. Patient follow-up lasted up to 10 years.</div></div><div><h3>Results</h3><div>MBS was associated with lower hazard of the primary composite outcome of CVD (HR, 0.54, 95 % CI, 0.49–0.60), and the secondary outcomes of incident HF (HR, 0.45, 95 % CI, 0.39–0.52), CAD (HR, 0.54, 95 % CI, 0.45–0.66), and cerebrovascular disease (HR, 0.64, 95 % CI, 0.53–0.77).</div></div><div><h3>Conclusions</h3><div>A lower risk of adverse cardiovascular outcomes was noted after MBS compared with GLP-1 RA therapy in patients with obesity.</div></div>","PeriodicalId":7771,"journal":{"name":"American journal of surgery","volume":"242 ","pages":"Article 116242"},"PeriodicalIF":2.7000,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Metabolic and bariatric surgery versus glucagon-like peptide-1 receptor agonist therapy: A comparison of cardiovascular outcomes in patients with obesity\",\"authors\":\"Soban Maan , Amir H. Sohail , Samia Aziz Sulaiman , Linta Mansoor , Ethan M. Cohen , Ayowumi A. Adekolu , Salim Abunnaja , Nova Szoka , Lawrence E. Tabone , Shyam Thakkar , Shailendra Singh\",\"doi\":\"10.1016/j.amjsurg.2025.116242\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background</h3><div>This study compared cardiovascular outcomes associated with metabolic and bariatric surgery (MBS) and glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy in individuals with obesity.</div></div><div><h3>Methods</h3><div>The TriNetX network was used to compare cardiovascular risk in adult patients with BMI ≥35 who underwent MBS with those who received GLP-1 RA therapy for ≥2 years. Primary outcome was cardiovascular disease (CVD), a composite of incident heart failure (HF), coronary artery disease (CAD), and cerebrovascular disease. Patient follow-up lasted up to 10 years.</div></div><div><h3>Results</h3><div>MBS was associated with lower hazard of the primary composite outcome of CVD (HR, 0.54, 95 % CI, 0.49–0.60), and the secondary outcomes of incident HF (HR, 0.45, 95 % CI, 0.39–0.52), CAD (HR, 0.54, 95 % CI, 0.45–0.66), and cerebrovascular disease (HR, 0.64, 95 % CI, 0.53–0.77).</div></div><div><h3>Conclusions</h3><div>A lower risk of adverse cardiovascular outcomes was noted after MBS compared with GLP-1 RA therapy in patients with obesity.</div></div>\",\"PeriodicalId\":7771,\"journal\":{\"name\":\"American journal of surgery\",\"volume\":\"242 \",\"pages\":\"Article 116242\"},\"PeriodicalIF\":2.7000,\"publicationDate\":\"2025-04-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"American journal of surgery\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0002961025000649\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/2/8 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q1\",\"JCRName\":\"SURGERY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"American journal of surgery","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0002961025000649","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/2/8 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"SURGERY","Score":null,"Total":0}

引用次数: 0

摘要

本研究比较了肥胖患者中代谢和减肥手术（MBS）和胰高血糖素样肽-1受体激动剂（GLP-1 RA）治疗相关的心血管结局。方法TriNetX网络用于比较BMI≥35接受MBS的成人患者与接受GLP-1 RA治疗≥2年的患者的心血管风险。主要结局是心血管疾病（CVD），由心力衰竭（HF）、冠状动脉疾病（CAD）和脑血管疾病组成。患者随访时间长达10年。结果smbs与主要复合结局CVD （HR, 0.54, 95% CI, 0.49-0.60）和次要结局HF （HR, 0.45, 95% CI, 0.39-0.52）、CAD （HR, 0.54, 95% CI, 0.45 - 0.66）和脑血管疾病（HR, 0.64, 95% CI, 0.53-0.77）的风险降低相关。结论与GLP-1 RA治疗相比，肥胖患者MBS治疗后心血管不良结局的风险较低。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

Metabolic and bariatric surgery versus glucagon-like peptide-1 receptor agonist therapy: A comparison of cardiovascular outcomes in patients with obesity

Background

This study compared cardiovascular outcomes associated with metabolic and bariatric surgery (MBS) and glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy in individuals with obesity.

Methods

The TriNetX network was used to compare cardiovascular risk in adult patients with BMI ≥35 who underwent MBS with those who received GLP-1 RA therapy for ≥2 years. Primary outcome was cardiovascular disease (CVD), a composite of incident heart failure (HF), coronary artery disease (CAD), and cerebrovascular disease. Patient follow-up lasted up to 10 years.

Results

MBS was associated with lower hazard of the primary composite outcome of CVD (HR, 0.54, 95 % CI, 0.49–0.60), and the secondary outcomes of incident HF (HR, 0.45, 95 % CI, 0.39–0.52), CAD (HR, 0.54, 95 % CI, 0.45–0.66), and cerebrovascular disease (HR, 0.64, 95 % CI, 0.53–0.77).

Conclusions

A lower risk of adverse cardiovascular outcomes was noted after MBS compared with GLP-1 RA therapy in patients with obesity.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

American journal of surgery 医学-外科

CiteScore

5.00

自引率

6.70%

发文量

570

审稿时长

56 days

期刊介绍： The American Journal of Surgery® is a peer-reviewed journal designed for the general surgeon who performs abdominal, cancer, vascular, head and neck, breast, colorectal, and other forms of surgery. AJS is the official journal of 7 major surgical societies* and publishes their official papers as well as independently submitted clinical studies, editorials, reviews, brief reports, correspondence and book reviews.